25 XP   0   0   10

Spero Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Spero Therapeutics Inc together

PenkeI guess you are interested in Spero Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Spero Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Spero Therapeutics Inc

I send you an email if I find something interesting about Spero Therapeutics Inc.

Quick analysis of Spero Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Spero Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
3.2%

What is your share worth?

Current worth
$1.98
Expected worth in 1 year
$2.56
How sure are you?
29.0%

+ What do you gain per year?

Total Gains per Share
$0.57
Return On Investment
39.1%

For what price can you sell your share?

Current Price per Share
$1.47
Expected price per share
$1.33 - $1.65
How sure are you?
50%

1. Valuation of Spero Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$1.47

Intrinsic Value Per Share

$-5.84 - $-6.75

Total Value Per Share

$-3.85 - $-4.77

2. Growth of Spero Therapeutics Inc (5 min.)




Is Spero Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$106.8m$51.7m$18.3m26.2%

How much money is Spero Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money$5.9m-$12.8m$18.8m316.6%
Net Profit Margin-779.0%-4,712.7%--

How much money comes from the company's main activities?

3. Financial Health of Spero Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#365 / 1016

Most Revenue
#211 / 1016

Most Profit
#109 / 1016

Most Efficient
#789 / 1016

What can you expect buying and holding a share of Spero Therapeutics Inc? (5 min.)

Welcome investor! Spero Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Spero Therapeutics Inc.

What can you expect buying and holding a share of Spero Therapeutics Inc?

First you should know what it really means to hold a share of Spero Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Spero Therapeutics Inc is $1.47. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Spero Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Spero Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.98. Based on the TTM, the Book Value Change Per Share is $0.14 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.06 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Spero Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.9564.6%0.117.2%-0.22-14.7%-0.23-16.0%-0.24-16.2%
Usd Book Value Change Per Share0.9967.2%0.149.8%-0.06-3.9%-0.01-0.6%0.064.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.1%
Usd Total Gains Per Share0.9967.2%0.149.8%-0.06-3.9%-0.01-0.6%0.074.4%
Usd Price Per Share1.47-1.40-3.29-8.93-7.61-
Price to Earnings Ratio0.39--1.95--1.34--7.39--6.79-
Price-to-Total Gains Ratio1.49--18.46--12.21--105.87--90.43-
Price to Book Ratio0.74-1.15-3.29-5.19-5.11-
Price-to-Total Gains Ratio1.49--18.46--12.21--105.87--90.43-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.47
Number of shares680
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.14-0.01
Usd Total Gains Per Share0.14-0.01
Gains per Quarter (680 shares)97.70-5.66
Gains per Year (680 shares)390.81-22.62
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
103913810-23-33
207827720-45-56
30117211630-68-79
40156315540-90-102
50195419450-113-125
60234523360-136-148
70273627270-158-171
80312731180-181-194
90351735090-204-217
100390839000-226-240

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%2.018.00.010.0%3.028.00.09.7%3.028.00.09.7%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%9.019.03.029.0%9.019.03.029.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%1.00.030.03.2%1.00.030.03.2%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%9.019.03.029.0%9.019.03.029.0%

Fundamentals of Spero Therapeutics Inc

About Spero Therapeutics Inc

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-12 18:59:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Spero Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Spero Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Spero Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 71.3% means that $0.71 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Spero Therapeutics Inc:

  • The MRQ is 71.3%. The company is making a huge profit. +2
  • The TTM is -779.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ71.3%TTM-779.0%+850.3%
TTM-779.0%YOY-4,712.7%+3,933.6%
TTM-779.0%5Y-2,764.2%+1,985.2%
5Y-2,764.2%10Y-2,402.1%-362.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ71.3%-197.2%+268.5%
TTM-779.0%-210.4%-568.6%
YOY-4,712.7%-279.3%-4,433.4%
5Y-2,764.2%-436.8%-2,327.4%
10Y-2,402.1%-599.3%-1,802.8%
1.1.2. Return on Assets

Shows how efficient Spero Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Spero Therapeutics Inc to the Biotechnology industry mean.
  • 28.1% Return on Assets means that Spero Therapeutics Inc generated $0.28 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Spero Therapeutics Inc:

  • The MRQ is 28.1%. Using its assets, the company is very efficient in making profit. +2
  • The TTM is 0.5%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ28.1%TTM0.5%+27.5%
TTM0.5%YOY-17.5%+18.0%
TTM0.5%5Y-12.4%+12.9%
5Y-12.4%10Y-21.8%+9.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ28.1%-13.6%+41.7%
TTM0.5%-12.9%+13.4%
YOY-17.5%-11.9%-5.6%
5Y-12.4%-14.2%+1.8%
10Y-21.8%-16.2%-5.6%
1.1.3. Return on Equity

Shows how efficient Spero Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Spero Therapeutics Inc to the Biotechnology industry mean.
  • 47.9% Return on Equity means Spero Therapeutics Inc generated $0.48 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Spero Therapeutics Inc:

  • The MRQ is 47.9%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 0.3%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ47.9%TTM0.3%+47.6%
TTM0.3%YOY-36.0%+36.3%
TTM0.3%5Y-19.1%+19.4%
5Y-19.1%10Y-289.9%+270.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ47.9%-17.0%+64.9%
TTM0.3%-16.1%+16.4%
YOY-36.0%-15.4%-20.6%
5Y-19.1%-20.0%+0.9%
10Y-289.9%-21.1%-268.8%

1.2. Operating Efficiency of Spero Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Spero Therapeutics Inc is operating .

  • Measures how much profit Spero Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Spero Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 68.0% means the company generated $0.68  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Spero Therapeutics Inc:

  • The MRQ is 68.0%. The company is operating very efficient. +2
  • The TTM is -843.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ68.0%TTM-843.6%+911.6%
TTM-843.6%YOY-4,044.5%+3,200.9%
TTM-843.6%5Y-2,644.9%+1,801.2%
5Y-2,644.9%10Y-2,406.4%-238.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ68.0%-286.1%+354.1%
TTM-843.6%-224.4%-619.2%
YOY-4,044.5%-288.4%-3,756.1%
5Y-2,644.9%-475.2%-2,169.7%
10Y-2,406.4%-624.7%-1,781.7%
1.2.2. Operating Ratio

Measures how efficient Spero Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.32 means that the operating costs are $0.32 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Spero Therapeutics Inc:

  • The MRQ is 0.320. The company is very efficient in keeping operating costs low. +2
  • The TTM is 15.797. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.320TTM15.797-15.476
TTM15.797YOY38.370-22.573
TTM15.7975Y35.740-19.944
5Y35.74010Y36.750-1.009
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3202.997-2.677
TTM15.7973.247+12.550
YOY38.3703.766+34.604
5Y35.7405.675+30.065
10Y36.7507.857+28.893

1.3. Liquidity of Spero Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Spero Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.53 means the company has $3.53 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Spero Therapeutics Inc:

  • The MRQ is 3.532. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.267. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.532TTM4.267-0.736
TTM4.267YOY3.467+0.800
TTM4.2675Y6.475-2.208
5Y6.47510Y6.305+0.170
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5323.930-0.398
TTM4.2674.251+0.016
YOY3.4675.436-1.969
5Y6.4756.045+0.430
10Y6.3056.363-0.058
1.3.2. Quick Ratio

Measures if Spero Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Spero Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 3.42 means the company can pay off $3.42 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Spero Therapeutics Inc:

  • The MRQ is 3.419. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.024. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.419TTM4.024-0.605
TTM4.024YOY3.518+0.506
TTM4.0245Y7.675-3.652
5Y7.67510Y7.813-0.137
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4193.629-0.210
TTM4.0244.065-0.041
YOY3.5185.397-1.879
5Y7.6755.993+1.682
10Y7.8136.277+1.536

1.4. Solvency of Spero Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Spero Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Spero Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.41 means that Spero Therapeutics Inc assets are financed with 41.4% credit (debt) and the remaining percentage (100% - 41.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Spero Therapeutics Inc:

  • The MRQ is 0.414. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.446. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.414TTM0.446-0.032
TTM0.446YOY0.474-0.028
TTM0.4465Y0.313+0.133
5Y0.31310Y0.324-0.011
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4140.332+0.082
TTM0.4460.334+0.112
YOY0.4740.268+0.206
5Y0.3130.366-0.053
10Y0.3240.390-0.066
1.4.2. Debt to Equity Ratio

Measures if Spero Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Spero Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 70.6% means that company has $0.71 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Spero Therapeutics Inc:

  • The MRQ is 0.706. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.810. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.706TTM0.810-0.104
TTM0.810YOY0.933-0.123
TTM0.8105Y0.529+0.281
5Y0.52910Y2.844-2.315
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7060.381+0.325
TTM0.8100.390+0.420
YOY0.9330.334+0.599
5Y0.5290.434+0.095
10Y2.8440.466+2.378

2. Market Valuation of Spero Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Spero Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Spero Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of 0.39 means the investor is paying $0.39 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Spero Therapeutics Inc:

  • The EOD is 0.387. Based on the earnings, the company is cheap. +2
  • The MRQ is 0.387. Based on the earnings, the company is cheap. +2
  • The TTM is -1.952. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.387MRQ0.3870.000
MRQ0.387TTM-1.952+2.339
TTM-1.952YOY-1.338-0.614
TTM-1.9525Y-7.394+5.442
5Y-7.39410Y-6.791-0.603
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.387-2.315+2.702
MRQ0.387-2.560+2.947
TTM-1.952-2.664+0.712
YOY-1.338-4.122+2.784
5Y-7.394-6.258-1.136
10Y-6.791-6.108-0.683
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Spero Therapeutics Inc:

  • The EOD is -1.132. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.132. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.670. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.132MRQ-1.1320.000
MRQ-1.132TTM-0.670-0.462
TTM-0.670YOY-8.052+7.382
TTM-0.6705Y-10.126+9.457
5Y-10.12610Y-9.237-0.889
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.132-3.067+1.935
MRQ-1.132-3.251+2.119
TTM-0.670-3.545+2.875
YOY-8.052-5.595-2.457
5Y-10.126-8.315-1.811
10Y-9.237-8.708-0.529
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Spero Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.74 means the investor is paying $0.74 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Spero Therapeutics Inc:

  • The EOD is 0.741. Based on the equity, the company is cheap. +2
  • The MRQ is 0.741. Based on the equity, the company is cheap. +2
  • The TTM is 1.146. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.741MRQ0.7410.000
MRQ0.741TTM1.146-0.405
TTM1.146YOY3.289-2.143
TTM1.1465Y5.190-4.044
5Y5.19010Y5.107+0.083
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.7411.905-1.164
MRQ0.7412.111-1.370
TTM1.1462.095-0.949
YOY3.2892.836+0.453
5Y5.1903.443+1.747
10Y5.1073.794+1.313
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Spero Therapeutics Inc.

3.1. Institutions holding Spero Therapeutics Inc

Institutions are holding 26.076% of the shares of Spero Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Anson Funds Management LP8.1090.781142976991381273.3207
2023-12-31Vanguard Group Inc3.10150.00011643757861615.5317
2023-09-30Atlas Venture Associates IX, LLC2.553413.9287135330300
2023-12-31ADAR1 Capital Management LLC2.01460.5609106771110677110
2023-12-31Alphabet Inc1.67920.060788997900
2023-12-31Murchinson Ltd.1.62780.220986270000
2023-12-31Renaissance Technologies Corp1.0330.00135474653000.0548
2023-12-31BlackRock Inc0.90680480599-1210-0.2511
2023-12-31Novo A/S0.88477.619646890200
2023-12-31Geode Capital Management, LLC0.77870.000141270700
2023-12-31Ameriprise Financial Inc0.76030.0002402963-60678-13.0873
2023-12-31Acadian Asset Management LLC0.64880.0023438567183226.4065
2023-12-31Awm Investment Company Inc0.62910.064533340000
2023-09-30OUP Management Co., LLC0.46990.677824907000
2023-12-31Millennium Management LLC0.28090.00011488572916324.3646
2023-12-31Bridgeway Capital Management, LLC0.25430.004313480000
2023-12-31State Street Corporation0.2463013051100
2023-12-31Dafna Capital Management LLC0.23590.04412500000
2023-12-31Squarepoint Ops LLC0.23170.0003122802-6695-5.17
2023-12-31Northern Trust Corp0.167708888100
Total 26.613623.966614104962+1324711+9.4%

3.2. Funds holding Spero Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv1.89550.0001102111614120.1385
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.09030.00158734200
2024-02-29Fidelity Extended Market Index0.44460.001239525-1161-0.4824
2023-12-31Bridgeway Ultra-Small Company Market0.25020.106713480000
2024-03-28iShares Micro-Cap ETF0.16690.01688991800
2023-09-30BlackRock Extended Mkt Composite0.1290.00066949900
2024-02-29Fidelity Total Market Index0.12540.00016756300
2024-03-31BlackRock Extended Equity Market K0.11260.000760654220.0363
2024-02-29Fidelity Series Total Market Index0.11130.00025996500
2023-12-31NT Ext Equity Mkt Idx Fd - L0.0660.00093554800
2023-12-31Northern Trust Extended Eq Market Idx0.0660.00093554800
2024-02-29Schwab Total Stock Market Index0.0530.00022856500
2024-02-29Spartan Total Market Index Pool E0.04820.00012599000
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.04550.00062450600
2024-02-29Fidelity Nasdaq Composite Index0.04390.000323675712243.0254
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.03650.000119689-875606-97.8008
2024-02-29Vanguard Instl Ttl Stk Mkt Idx InstlPls0.03650.00011968900
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.03650.000619682370.1883
2024-02-29Vanguard Balanced Index Inv0.02810.000115123-4115-21.39
2024-02-29Spartan Extended Market Index Pool E0.02280.000812268116110.4529
Total 4.80880.13192590665-871128-33.6%

3.3. Insider Transactions

Insiders are holding 20.376% of the shares of Spero Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-09-13Kamal HamedSELL394961.27
2023-08-29Sath ShuklaSELL41631.3
2023-08-28Ankit MahadeviaSELL90401.26
2023-08-28Timothy KeutzerSELL18541.26

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Spero Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.9870.144+587%-0.057+106%-0.008+101%0.064+1443%
Book Value Per Share--1.9841.300+53%0.960+107%1.585+25%1.330+49%
Current Ratio--3.5324.267-17%3.467+2%6.475-45%6.305-44%
Debt To Asset Ratio--0.4140.446-7%0.474-13%0.313+32%0.324+28%
Debt To Equity Ratio--0.7060.810-13%0.933-24%0.529+33%2.844-75%
Dividend Per Share----0%-0%-0%0.001-100%
Eps--0.9500.106+798%-0.215+123%-0.235+125%-0.238+125%
Free Cash Flow Per Share---0.325-0.153-53%-0.036-89%-0.224-31%-0.208-36%
Free Cash Flow To Equity Per Share---0.325-0.152-53%-0.173-47%-0.037-89%0.038-953%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---6.750--------
Intrinsic Value_10Y_min---5.839--------
Intrinsic Value_1Y_max---0.655--------
Intrinsic Value_1Y_min---0.643--------
Intrinsic Value_3Y_max---1.984--------
Intrinsic Value_3Y_min---1.893--------
Intrinsic Value_5Y_max---3.332--------
Intrinsic Value_5Y_min---3.092--------
Market Cap79187577.0000%79187577.00075147394.500+5%177377479.025-55%480905616.430-84%409884768.761-81%
Net Profit Margin--0.713-7.790+1193%-47.127+6712%-27.642+3978%-24.021+3470%
Operating Margin--0.680-8.436+1341%-40.445+6049%-26.449+3990%-24.064+3639%
Operating Ratio--0.32015.797-98%38.370-99%35.740-99%36.750-99%
Pb Ratio0.7410%0.7411.146-35%3.289-77%5.190-86%5.107-85%
Pe Ratio0.3870%0.387-1.952+605%-1.338+446%-7.394+2012%-6.791+1856%
Price Per Share1.4700%1.4701.395+5%3.293-55%8.927-84%7.609-81%
Price To Free Cash Flow Ratio-1.1320%-1.132-0.670-41%-8.052+611%-10.126+795%-9.237+716%
Price To Total Gains Ratio1.4890%1.489-18.460+1340%-12.210+920%-105.869+7211%-90.433+6174%
Quick Ratio--3.4194.024-15%3.518-3%7.675-55%7.813-56%
Return On Assets--0.2810.005+5265%-0.175+162%-0.124+144%-0.218+177%
Return On Equity--0.4790.003+15918%-0.360+175%-0.191+140%-2.899+705%
Total Gains Per Share--0.9870.144+587%-0.057+106%-0.008+101%0.065+1413%
Usd Book Value--106894000.00070055000.000+53%51703500.000+107%85394600.000+25%71639838.710+49%
Usd Book Value Change Per Share--0.9870.144+587%-0.057+106%-0.008+101%0.064+1443%
Usd Book Value Per Share--1.9841.300+53%0.960+107%1.585+25%1.330+49%
Usd Dividend Per Share----0%-0%-0%0.001-100%
Usd Eps--0.9500.106+798%-0.215+123%-0.235+125%-0.238+125%
Usd Free Cash Flow---17493000.000-8248750.000-53%-1932750.000-89%-12069850.000-31%-11199129.032-36%
Usd Free Cash Flow Per Share---0.325-0.153-53%-0.036-89%-0.224-31%-0.208-36%
Usd Free Cash Flow To Equity Per Share---0.325-0.152-53%-0.173-47%-0.037-89%0.038-953%
Usd Market Cap79187577.0000%79187577.00075147394.500+5%177377479.025-55%480905616.430-84%409884768.761-81%
Usd Price Per Share1.4700%1.4701.395+5%3.293-55%8.927-84%7.609-81%
Usd Profit--51191000.0005941750.000+762%-12870000.000+125%-12844850.000+125%-11647838.710+123%
Usd Revenue--71827000.00024707000.000+191%12131643.250+492%9011978.650+697%5998824.935+1097%
Usd Total Gains Per Share--0.9870.144+587%-0.057+106%-0.008+101%0.065+1413%
 EOD+0 -0MRQTTM+24 -9YOY+22 -115Y+19 -1410Y+20 -15

4.2. Fundamental Score

Let's check the fundamental score of Spero Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-150.387
Price to Book Ratio (EOD)Between0-10.741
Net Profit Margin (MRQ)Greater than00.713
Operating Margin (MRQ)Greater than00.680
Quick Ratio (MRQ)Greater than13.419
Current Ratio (MRQ)Greater than13.532
Debt to Asset Ratio (MRQ)Less than10.414
Debt to Equity Ratio (MRQ)Less than10.706
Return on Equity (MRQ)Greater than0.150.479
Return on Assets (MRQ)Greater than0.050.281
Total10/10 (100.0%)

4.3. Technical Score

Let's check the technical score of Spero Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5034.312
Ma 20Greater thanMa 501.674
Ma 50Greater thanMa 1001.632
Ma 100Greater thanMa 2001.510
OpenGreater thanClose1.500
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets182,390
Total Liabilities75,496
Total Stockholder Equity106,894
 As reported
Total Liabilities 75,496
Total Stockholder Equity+ 106,894
Total Assets = 182,390

Assets

Total Assets182,390
Total Current Assets131,208
Long-term Assets51,182
Total Current Assets
Cash And Cash Equivalents 76,333
Net Receivables 50,697
Other Current Assets 4,178
Total Current Assets  (as reported)131,208
Total Current Assets  (calculated)131,208
+/-0
Long-term Assets
Property Plant Equipment 4,157
Long-term Assets Other 435
Long-term Assets  (as reported)51,182
Long-term Assets  (calculated)4,592
+/- 46,590

Liabilities & Shareholders' Equity

Total Current Liabilities37,153
Long-term Liabilities38,343
Total Stockholder Equity106,894
Total Current Liabilities
Short-term Debt 1,718
Accounts payable 1,378
Other Current Liabilities 6,944
Total Current Liabilities  (as reported)37,153
Total Current Liabilities  (calculated)10,040
+/- 27,113
Long-term Liabilities
Capital Lease Obligations 5,543
Long-term Liabilities Other 87
Long-term Liabilities  (as reported)38,343
Long-term Liabilities  (calculated)5,630
+/- 32,713
Total Stockholder Equity
Common Stock53
Retained Earnings -391,072
Other Stockholders Equity 497,913
Total Stockholder Equity (as reported)106,894
Total Stockholder Equity (calculated)106,894
+/-0
Other
Capital Stock53
Cash and Short Term Investments 76,333
Common Stock Shares Outstanding 53,108
Current Deferred Revenue27,113
Liabilities and Stockholders Equity 182,390
Net Debt -70,790
Net Invested Capital 106,894
Net Working Capital 94,055
Property Plant and Equipment Gross 7,775
Short Long Term Debt Total 5,543



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302015-12-31
> Total Assets 
7,176
0
13,772
40,099
40,099
31,550
31,550
93,479
72,592
136,120
129,006
124,650
122,489
112,510
106,103
109,894
97,545
157,040
153,451
143,440
119,594
144,691
171,072
145,830
63,628
64,476
124,802
112,546
98,885
107,101
182,390
182,390107,10198,885112,546124,80264,47663,628145,830171,072144,691119,594143,440153,451157,04097,545109,894106,103112,510122,489124,650129,006136,12072,59293,47931,55031,55040,09940,09913,77207,176
   > Total Current Assets 
5,988
0
11,872
37,475
37,475
26,959
26,959
87,288
70,492
133,723
115,443
115,702
112,690
103,970
82,045
97,960
85,286
142,667
126,906
129,492
106,316
131,769
157,872
132,704
51,954
52,887
109,107
101,662
88,349
102,222
131,208
131,208102,22288,349101,662109,10752,88751,954132,704157,872131,769106,316129,492126,906142,66785,28697,96082,045103,970112,690115,702115,443133,72370,49287,28826,95926,95937,47537,47511,87205,988
       Cash And Cash Equivalents 
5,691
0
10,315
36,299
36,299
25,373
25,373
87,288
48,715
40,480
34,080
49,395
71,133
45,597
29,730
64,363
65,342
125,242
85,209
77,042
71,562
112,859
112,584
72,111
45,401
50,446
109,107
96,254
77,690
93,825
76,333
76,33393,82577,69096,254109,10750,44645,40172,111112,584112,85971,56277,04285,209125,24265,34264,36329,73045,59771,13349,39534,08040,48048,71587,28825,37325,37336,29936,29910,31505,691
       Short-term Investments 
0
0
0
0
0
0
0
22,841
17,922
90,745
81,363
56,997
32,275
48,259
52,315
24,478
6,018
2,002
41,697
38,634
27,656
10,558
33,818
49,855
0
0
0
0
0
0
0
000000049,85533,81810,55827,65638,63441,6972,0026,01824,47852,31548,25932,27556,99781,36390,74517,92222,8410000000
       Net Receivables 
10
0
304
228
228
537
537
2,943
2,624
1,276
1,298
1,384
2,994
6,438
8,546
3,436
4,769
8,126
6,176
8,622
2,197
2,584
2,641
1,991
1,578
953
1,084
1,865
2,088
2,989
50,697
50,6972,9892,0881,8651,0849531,5781,9912,6412,5842,1978,6226,1768,1264,7693,4368,5466,4382,9941,3841,2981,2762,6242,943537537228228304010
       Other Current Assets 
287
0
1,253
0
948
1,049
3,760
1,828
1,231
1,222
7,478
7,926
6,288
3,676
4,823
5,683
9,157
7,297
6,063
5,194
4,901
5,768
8,829
8,747
4,975
1,488
3,379
3,543
8,571
5,408
4,178
4,1785,4088,5713,5433,3791,4884,9758,7478,8295,7684,9015,1946,0637,2979,1575,6834,8233,6766,2887,9267,4781,2221,2311,8283,7601,04994801,2530287
   > Long-term Assets 
0
0
1,900
0
2,624
4,591
4,591
6,191
2,100
2,397
13,563
8,948
9,799
8,540
24,058
11,934
12,259
14,373
26,545
13,948
13,278
12,922
13,200
13,126
11,674
11,589
15,695
10,884
10,536
4,879
51,182
51,1824,87910,53610,88415,69511,58911,67413,12613,20012,92213,27813,94826,54514,37312,25911,93424,0588,5409,7998,94813,5632,3972,1006,1914,5914,5912,62401,90000
       Property Plant Equipment 
949
0
1,500
1,330
1,330
1,264
1,164
1,164
975
2,191
2,893
7,233
6,876
6,463
7,148
6,928
6,842
9,162
8,783
8,425
8,067
7,710
7,556
7,197
6,207
5,850
5,492
5,144
4,796
4,445
4,157
4,1574,4454,7965,1445,4925,8506,2077,1977,5567,7108,0678,4258,7839,1626,8426,9287,1486,4636,8767,2332,8932,1919751,1641,1641,2641,3301,3301,5000949
       Long-term Assets Other 
0
0
400
0
1,294
3,327
50
5,027
1,125
206
10,670
1,715
2,923
2,077
16,910
5,006
5,417
5,211
17,762
5,523
5,211
5,212
5,644
5,929
5,467
5,739
10,203
5,740
5,740
434
435
4354345,7405,74010,2035,7395,4675,9295,6445,2125,2115,52317,7625,2115,4175,00616,9102,0772,9231,71510,6702061,1255,027503,3271,294040000
> Total Liabilities 
7,433
0
7,411
6,844
6,844
7,273
7,273
8,522
6,924
10,568
13,151
11,321
12,820
19,476
31,529
27,467
23,831
24,251
21,411
24,594
29,342
32,796
82,783
83,357
27,705
31,992
48,868
47,707
44,103
53,396
75,496
75,49653,39644,10347,70748,86831,99227,70583,35782,78332,79629,34224,59421,41124,25123,83127,46731,52919,47612,82011,32113,15110,5686,9248,5227,2737,2736,8446,8447,41107,433
   > Total Current Liabilities 
6,421
0
6,918
6,411
6,411
6,874
6,874
8,157
6,601
10,278
12,318
6,618
8,249
15,058
26,663
22,741
19,012
17,562
14,343
17,763
12,826
17,258
18,670
69,199
14,229
16,225
21,649
22,987
17,324
25,461
37,153
37,15325,46117,32422,98721,64916,22514,22969,19918,67017,25812,82617,76314,34317,56219,01222,74126,66315,0588,2496,61812,31810,2786,6018,1576,8746,8746,4116,4116,91806,421
       Short-term Debt 
0
0
0
0
0
217
223
223
223
223
223
639
571
442
928
932
936
1,526
947
980
1,008
1,042
1,362
1,369
1,528
1,683
1,690
1,697
1,704
1,711
1,718
1,7181,7111,7041,6971,6901,6831,5281,3691,3621,0421,0089809471,52693693292844257163922322322322322321700000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
639
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000063900000000000
       Accounts payable 
1,794
0
1,139
1,368
1,368
2,011
7,791
3,470
705
1,364
3,603
557
1,039
2,524
4,147
8,951
1,562
2,480
1,155
3,825
1,632
3,161
1,101
4,780
1,711
2,582
617
583
1,310
1,103
1,378
1,3781,1031,3105836172,5821,7114,7801,1013,1611,6323,8251,1552,4801,5628,9514,1472,5241,0395573,6031,3647053,4707,7912,0111,3681,3681,13901,794
       Other Current Liabilities 
4,627
0
5,779
356
5,043
4,863
143
4,687
5,896
8,914
8,715
223
223
223
22,516
13,790
17,450
15,082
13,188
13,938
9,007
11,356
14,350
60,957
8,626
8,234
8,973
8,862
5,601
8,774
6,944
6,9448,7745,6018,8628,9738,2348,62660,95714,35011,3569,00713,93813,18815,08217,45013,79022,5162232232238,7158,9145,8964,6871434,8635,0433565,77904,627
   > Long-term Liabilities 
0
0
493
0
433
399
399
365
323
290
833
4,703
4,571
4,418
4,866
4,726
4,819
6,689
7,068
6,831
16,516
15,538
64,113
14,158
13,476
15,767
27,219
24,720
26,779
27,935
38,343
38,34327,93526,77924,72027,21915,76713,47614,15864,11315,53816,5166,8317,0686,6894,8194,7264,8664,4184,5714,703833290323365399399433049300
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
312
293
256
249
205
196
186
177
168
158
148
0
0
0
107
0
85
0
0
0
00085010700014815816817718619620524925629331200000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
-217
-223
-223
-223
-223
-223
4,391
4,278
4,162
4,617
4,521
4,623
6,503
6,891
6,663
6,430
6,191
5,973
5,726
5,473
5,218
4,957
4,685
4,407
4,120
3,825
3,8254,1204,4074,6854,9575,2185,4735,7265,9736,1916,4306,6636,8916,5034,6234,5214,6174,1624,2784,391-223-223-223-223-223-21700000
       Warrants
0
0
0
0
0
106,110
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000106,11000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
312
293
256
249
205
196
6,503
6,891
6,663
6,430
6,191
48,552
128
117
107
96
4,685
72
62
87
8762724,6859610711712848,5526,1916,4306,6636,8916,50319620524925629331200000000000
       Deferred Long Term Liability 
36
0
0
272
272
399
365
327
323
290
833
0
0
0
0
0
0
0
0
0
9,928
9,199
0
0
0
10,442
0
19,950
0
0
0
00019,950010,4420009,1999,9280000000008332903233273653992722720036
> Total Stockholder Equity
196
0
10,169
-37,516
31,783
23,916
84,602
84,957
65,313
125,197
115,855
112,974
109,314
92,679
74,574
82,427
73,714
132,789
132,040
118,846
90,252
111,895
88,289
62,473
35,923
32,484
75,934
64,839
54,782
53,705
106,894
106,89453,70554,78264,83975,93432,48435,92362,47388,289111,89590,252118,846132,040132,78973,71482,42774,57492,679109,314112,974115,855125,19765,31384,95784,60223,91631,783-37,51610,1690196
   Common Stock
0
0
7,924
2
8
0
14
14
14
18
17
17
19
19
19
20
21
26
29
30
30
32
32
33
35
43
52
53
53
53
53
535353535243353332323030292621201919191717181414140827,92400
   Retained Earnings Total Equity000-427,1440-440,649000-338,223-315,702-297,130-277,707-259,122-240,186-222,685-199,427-174,441-156,724-143,574-138,502-127,903-117,440-107,484-96,840-82,19400000
   Accumulated Other Comprehensive Income 
0
0
-290
0
-455
0
-643
-643
-15
-23
-28
1
6
18
16
-19
15
1
-7
-3
-2
-2
-2
-6
0
0
0
0
0
0
0
0000000-6-2-2-2-3-7115-19161861-28-23-15-643-6430-4550-29000
   Capital Surplus 
0
0
0
0
0
0
181,428
182,042
182,754
253,105
254,013
256,530
266,013
267,083
273,966
305,111
313,864
391,881
409,722
415,946
405,923
450,085
0
0
0
473,090
0
491,930
0
0
0
000491,9300473,090000450,085405,923415,946409,722391,881313,864305,111273,966267,083266,013256,530254,013253,105182,754182,042181,428000000
   Treasury Stock0000000000000000000000000000000
   Other Stockholders Equity 
0
0
8,214
0
104,207
106,110
0
182,071
182,739
253,082
254,812
256,531
266,019
267,101
275,497
305,092
313,879
391,881
409,722
415,946
405,923
450,085
455,719
462,735
464,860
473,090
489,760
491,930
493,787
495,915
497,913
497,913495,915493,787491,930489,760473,090464,860462,735455,719450,085405,923415,946409,722391,881313,879305,092275,497267,101266,019256,531254,812253,082182,739182,0710106,110104,20708,21400



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue96,735
Cost of Revenue-367
Gross Profit96,36896,368
 
Operating Income (+$)
Gross Profit96,368
Operating Expense-76,627
Operating Income19,74119,741
 
Operating Expense (+$)
Research Development51,073
Selling General Administrative25,554
Selling And Marketing Expenses0
Operating Expense76,62776,627
 
Net Interest Income (+$)
Interest Income3,937
Interest Expense-0
Other Finance Cost-0
Net Interest Income3,937
 
Pretax Income (+$)
Operating Income19,741
Net Interest Income3,937
Other Non-Operating Income Expenses0
Income Before Tax (EBT)25,40414,078
EBIT - interestExpense = 19,741
25,404
22,806
Interest Expense0
Earnings Before Interest and Taxes (EBIT)19,74125,404
Earnings Before Interest and Taxes (EBITDA)20,108
 
After tax Income (+$)
Income Before Tax25,404
Tax Provision-2,598
Net Income From Continuing Ops22,80622,806
Net Income22,806
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses76,994
Total Other Income/Expenses Net5,663-3,937
 

Technical Analysis of Spero Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Spero Therapeutics Inc. The general trend of Spero Therapeutics Inc is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Spero Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Spero Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 1.65 < 1.65 < 1.65.

The bearish price targets are: 1.45 > 1.35 > 1.33.

Tweet this
Spero Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Spero Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Spero Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Spero Therapeutics Inc. The current macd is -0.04174142.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Spero Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Spero Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Spero Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Spero Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartSpero Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Spero Therapeutics Inc. The current adx is 33.10.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Spero Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Spero Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Spero Therapeutics Inc. The current sar is 1.74272839.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Spero Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Spero Therapeutics Inc. The current rsi is 34.31. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Spero Therapeutics Inc Daily Relative Strength Index (RSI) ChartSpero Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Spero Therapeutics Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Spero Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Spero Therapeutics Inc Daily Stochastic Oscillator ChartSpero Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Spero Therapeutics Inc. The current cci is -189.77854494.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Spero Therapeutics Inc Daily Commodity Channel Index (CCI) ChartSpero Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Spero Therapeutics Inc. The current cmo is -45.07325265.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Spero Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartSpero Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Spero Therapeutics Inc. The current willr is -97.14285714.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Spero Therapeutics Inc Daily Williams %R ChartSpero Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Spero Therapeutics Inc.

Spero Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Spero Therapeutics Inc. The current atr is 0.0912795.

Spero Therapeutics Inc Daily Average True Range (ATR) ChartSpero Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Spero Therapeutics Inc. The current obv is 303,995,377.

Spero Therapeutics Inc Daily On-Balance Volume (OBV) ChartSpero Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Spero Therapeutics Inc. The current mfi is 43.11.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Spero Therapeutics Inc Daily Money Flow Index (MFI) ChartSpero Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Spero Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-21MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-07MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Spero Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Spero Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5034.312
Ma 20Greater thanMa 501.674
Ma 50Greater thanMa 1001.632
Ma 100Greater thanMa 2001.510
OpenGreater thanClose1.500
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Spero Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Spero Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Spero Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Spero Therapeutics Inc

I send you an email if I find something interesting about Spero Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Spero Therapeutics Inc.

Receive notifications about Spero Therapeutics Inc in your mailbox!